Literature DB >> 8691109

Selective toxic effects of tamoxifen on osteoclasts: comparison with the effects of oestrogen.

T R Arnett1, R Lindsay, J M Kilb, B S Moonga, M Spowage, D W Dempster.   

Abstract

We investigated the actions of the trans- and cis-isomers of tamoxifen on the function of neonatal rat osteoclasts in vitro. Both compounds inhibited resorption pit formation by osteoclast-containing mixed bone cell cultures incubated for 24 h on cortical bone slices. Cell counts revealed that the inhibition was closely related to a cytotoxic effect, to which osteoclasts appeared particularly sensitive. Partial inhibition of resorption was seen in the presence of 2 microM trans-tamoxifen, whereas complete abolition of resorption and osteoclast viability occurred with 10 microM trans-tamoxifen; survival of mononuclear cells was unimpaired at either concentration. Cis-tamoxifen appeared to be slightly more toxic, with significant inhibitions of osteoclast viability and thus resorption pit formation at a concentration of 2 microM, and also of mononuclear cell numbers at 10 microM. Time-lapse video observations indicated that osteoclast death occurred rapidly (within 2-3 h) following exposure to 10 microM of either trans-tamoxifen or cis-tamoxifen. The morphological appearance of the dying cells was consistent with apoptosis. These results may help to explain the anti-resorptive action of tamoxifen seen in vivo in rats and humans. In contrast, oestradiol-17 beta consistently exerted no significant effects on resorption pit formation by rat osteoclasts over 24 h, even at grossly supraphysiological concentrations (up to 10 microM).

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8691109     DOI: 10.1677/joe.0.1490503

Source DB:  PubMed          Journal:  J Endocrinol        ISSN: 0022-0795            Impact factor:   4.286


  13 in total

Review 1.  The molecular mechanism behind bone remodelling: a review.

Authors:  Peter Proff; Piero Römer
Journal:  Clin Oral Investig       Date:  2009-03-25       Impact factor: 3.573

2.  Establishment of a cell-free system of neuronal apoptosis: comparison of premitochondrial, mitochondrial, and postmitochondrial phases.

Authors:  H M Ellerby; S J Martin; L M Ellerby; S S Naiem; S Rabizadeh; G S Salvesen; C A Casiano; N R Cashman; D R Green; D E Bredesen
Journal:  J Neurosci       Date:  1997-08-15       Impact factor: 6.167

Review 3.  Apoptosis in bone physiology and disease.

Authors:  D E Hughes; B F Boyce
Journal:  Mol Pathol       Date:  1997-06

4.  Construction of a database for the evaluation and the clinical management of patients with breast cancer treated with antiestrogens and/or aromatase inhibitors.

Authors:  Francesca Giusti; Silva Ottanelli; Laura Masi; Antonietta Amedei; Maria Luisa Brandi; Alberto Falchetti
Journal:  Clin Cases Miner Bone Metab       Date:  2011-01

Review 5.  CSF1R as a Therapeutic Target in Bone Diseases: Obvious but Not so Simple.

Authors:  David A Hume; Lena Batoon; Anuj Sehgal; Sahar Keshvari; Katharine M Irvine
Journal:  Curr Osteoporos Rep       Date:  2022-10-05       Impact factor: 5.163

6.  ATP is a potent stimulator of the activation and formation of rodent osteoclasts.

Authors:  M S Morrison; L Turin; B F King; G Burnstock; T R Arnett
Journal:  J Physiol       Date:  1998-09-01       Impact factor: 5.182

7.  Differential effects of selective oestrogen receptor modulators (SERMs) tamoxifen, ospemifene and raloxifene on human osteoclasts in vitro.

Authors:  H Michael; P L Härkönen; L Kangas; H K Väänänen; T A Hentunen
Journal:  Br J Pharmacol       Date:  2007-04-10       Impact factor: 8.739

Review 8.  Cancer treatment-related bone disease.

Authors:  Sue A Brown; Theresa A Guise
Journal:  Crit Rev Eukaryot Gene Expr       Date:  2009       Impact factor: 1.807

9.  Estrogen inhibits bone resorption by directly inducing apoptosis of the bone-resorbing osteoclasts.

Authors:  T Kameda; H Mano; T Yuasa; Y Mori; K Miyazawa; M Shiokawa; Y Nakamaru; E Hiroi; K Hiura; A Kameda; N N Yang; Y Hakeda; M Kumegawa
Journal:  J Exp Med       Date:  1997-08-18       Impact factor: 14.307

10.  The effects of a novel hormonal breast cancer therapy, endoxifen, on the mouse skeleton.

Authors:  Anne Gingery; Malayannan Subramaniam; Kevin S Pitel; Jordan M Reese; Muzaffer Cicek; Laurence B Lindenmaier; James N Ingle; Matthew P Goetz; Russell T Turner; Urszula T Iwaniec; Thomas C Spelsberg; John R Hawse
Journal:  PLoS One       Date:  2014-05-22       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.